ClinicalTrials.gg
RecruitingNCT07476196POWERUpdated Mar 20, 2026

Poland-Italy Aortic Research Bridge Real World Registry

An observational study in Abdominal Aortic Aneurysm, sponsored by American Heart of Poland. Recruiting at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by American Heart of Poland · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Aortic Aneurysm, Abdominal with a site in Poland — 6 open to participants now, 6 under way, none of them phase 3. Aortic Aneurysm, Abdominal · Poland.

Started
2026
the only one that year
Observational
8 of 15
3 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
American Heart of Poland

Among the 15 studies in Aortic Aneurysm, Abdominal with a site in Poland, this one is the only one that started in 2026, is one of 8 observational ones, and was the 15th registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

6 of the 15 studies in Aortic Aneurysm, Abdominal with a site in Poland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Aortic Aneurysm, Abdominal with a site in Poland, or all of them as a file.
02

Study summary

Objective To pragmatically collect and analyze patient-level clinical, procedural, and outcome data from participating centers in Italy and Poland on the use of the PERCUTEK Tycheseal™ stent-graft system for the endovascular repair of abdominal aortic aneurysms. The study aims to generate high-quality, real-world evidence on the technical success, safety, and mid-term outcomes of the device.

Study Design This is a pragmatic, observational, multicenter physician-initiated registry that will collect patient-level data for all eligible patients undergoing PERCUTEK Tycheseal™ device implantation. Each site will enter data into a standardized paper case report form (CRF), including demographic, anatomical, procedural, and follow-up variables. Sites will be expected to comply with data entry timelines and quality control checks. The total projected enrollment is 120-200 patients across all sites over an expected 18 month inclusion period.

The target enrollment is 120-200 patients across all participating sites.

Read the detailed description

Background and Rationale

Abdominal Aortic Aneurysm (AAA): Clinical Burden and Unmet Needs Abdominal aortic aneurysm (AAA) is a progressive and potentially fatal vascular disease defined as a localized dilatation of the abdominal aorta exceeding 1.5 times its normal diameter, typically ≥3.0 cm. The pathophysiology of AAA involves complex interplay between genetic predisposition, chronic inflammation, extracellular matrix degradation, and biomechanical wall stress. Risk factors for AAA include advanced age, male sex, smoking, hypertension, dyslipidemia, and family history. Notably, population based screening studies have shown that up to 5-8% of men over the age of 65 harbor asymptomatic AAAs, many of which are at risk of expansion and eventual rupture if left untreated. The clinical importance of timely diagnosis and treatment of AAA lies in its natural history: once the aneurysm reaches a critical threshold-commonly 5.5 cm in diameter in men or 5.0 cm in women-the risk of rupture increases substantially. Aneurysm rupture is associated with extremely high mortality, with up to 90% of patients dying before reaching the hospital or during emergency intervention. Consequently, elective repair is indicated in appropriately selected patients based on aneurysm size, growth rate, symptomatology, and anatomical feasibility.

Advances and Challenges in Endovascular Aneurysm Repair (EVAR) Over the past two decades, endovascular aneurysm repair (EVAR) has largely supplanted open surgical repair (OSR) as the preferred modality for treating infrarenal AAA in anatomically suitable patients. EVAR offers several perioperative advantages, including reduced operative blood loss, shorter procedure times, lower 30-day mortality rates, and faster postoperative recovery. These benefits make EVAR especially attractive for elderly patients and those with significant comorbidities who may not tolerate open surgery.

Despite these advantages, EVAR is not without limitations. Long-term surveillance is required due to risks of late complications such as graft migration, endoleak formation (particularly types I and III), aneurysm sac expansion, and device thrombosis. These complications may necessitate secondary interventions and contribute to long-term morbidity. Additionally, anatomical constraints such as short or highly angulated necks, calcification, thrombus burden, and tortuous iliac arteries may preclude the safeuse of some endograft systems. As a result, device selection plays a crucial role in procedural success and long-term outcomes.

The Poland-Italy Aortic Research Bridge Real World Registry (POWER) is a pragmatic, observational, multicenter registry designed to systematically collect real-world data on the use of the PERCUTEK Tycheseal™Tri-Modular Endograft System in patients undergoing endovascular repair of abdominal aortic aneurysms (AAA).

Study Type This is a non-randomized, open-label, post-market physician-initiated clinical investigation. It does not involve experimental treatments or random allocation of interventions, and no comparator arm is included.

Objectives

  • To assess technical success and safety outcomes associated with the use of the PERCUTEK Tycheseal™system.
  • To evaluate mid-term clinical outcomes, including aneurysm sac behavior, endoleak rates, and device-related complications over a follow-up period of up to 24 months.

Participating Countries and Sites

  • Multicenter registry with sites in Poland and Italy.
  • Sites must demonstrate documented experience in aortic endovascular repair.
  • Each participating center must have local ethics approval and assign a trained data manager and a site principal investigator, unless a general (e.g. national or regional) ethics committee approval is applicable.

Estimated Enrollment

  • A total of 120-200 patients will be enrolled consecutively over approximately 18 months.

Each subject will be followed for up to 24 months post-implantation, with assessments at baseline, discharge, 1 month, 12 months and 24 months.

The PERCUTEK Tycheseal™Endograft System: Design Rationale The PERCUTEK Tycheseal™ system is a tri-modular stent graft platform designed for the treatment of infrarenal AAA. It consists of a main body and two iliac limb components, each optimized for precision deployment, modular adaptability, and enhanced seal zone conformity. The device is intended to address common anatomical challenges by accommodating a wide range of aortic neck diameters (main body proximal graft diameters: 20-36 mm, with 10-20% of oversizing), tolerating moderate angulation (up to 75°), and facilitating reliable fixation and sealing even in anatomically complex patients.

The PERCUTEK Tycheseal™ system features a low-profile delivery system, radiopaque markers for fluoroscopic visibility, and graft materials engineered for biocompatibility and durability. Early use in single-center case series and preliminary feasibility studies suggests that the device offers favorable deliverability, short procedure duration, and high technical success. However, robust, pragmatic, multicenter data in real-world settings are still lacking, which limits broader confidence in its long-term safety and performance.

Rationale for the POWER Registry The Poland-Italy Aortic Research Bridge Real World Registry (POWER) has been established to pragmatically evaluate the use of the PERCUTEK Tycheseal™ stent graft system in a real-world clinical environment across multiple high-volume European centers. This physician-initiated registry aims to fill a critical evidence gap by generating longitudinal, patient-level data on technical feasibility, clinical outcomes, and device-related complications over a 12-24- month period.

Several compelling factors justify the need for this registry:

  • Real-World Generalizability: Unlike tightly controlled randomized trials, the POWER Registry reflects actual clinical practice, encompassing diverse operator experience levels, institutional protocols, and patient anatomies.
  • Post-Market Surveillance: As the PERCUTEK Tycheseal™ system expands into routine use, structured post-market follow-up becomes essential to detect rare adverse events and performance trends.
  • Multinational Collaboration: By including centers from both Poland and Italy, the registry promotes transnational harmonization of endovascular standards and facilitates benchmarking of regional clinical outcomes.
  • Clinical Decision Support: The findings from this registry will provide procedural insights and safety benchmarks that can inform clinical decision-making, guideline development, and payer evaluations.

Through detailed documentation of implantation success, early and mid-term complications, and follow-up imaging, the POWER Registry will support an evidencebased understanding of the PERCUTEK Tycheseal™system's performance. The use of standardized paper CRFs, centralized data coordination, and optional site-level aggregate submissions ensures a flexible yet rigorous data capture approach. Ultimately, the POWER Registry aligns with contemporary regulatory and clinical imperatives for post-market device surveillance, and its findings are expected to directly contribute to the refinement of EVAR indications, device iteration, and patient centered care in AAA management.

03

Conditions studied

  • Abdominal Aortic Aneurysm

Keywords

  • Abdominal aortic aneurysm
  • Endovascular Aneurysm Repair
  • PERCUTEK Tycheseal™
  • vascular disease
  • stent graft
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with abdominal aortic aneurysm

Eligibility criteria

Anatomical Inclusion Criteria (as per IFU):

  • Morphologically suitable aneurysm
  • Neck length ≥ 10 mm
  • Neck diameter suitable for 20-36 mm body (considering 10-20% of oversizing)
  • Neck angle: infrarenal ≤ 75°
  • Distal seal zone ≥ 10 mm
  • Iliac arteries 8-20 mm diameter

Patient Inclusion Criteria:

  • Age >18 years
  • Signed
  • Pregnancy test for premenopausal women

Exclusion Criteria:

  • Anatomical unsuitability
  • Subject has a \< 1 year
  • Circumferential thrombus in neck
  • Ruptured aneurysm
  • Renal arteries from aneurysm sac
  • Dominant IMA with obstructed visceral vessels
  • Internal iliac artery aneurysms (unless pre-treated)
  • Subject has a known dual antiplatelets therapy or contrast media,
  • Selected patients with chronic kidney failure (CKF) can undergo EVAR using standard contrast or CO2 as contrast agent.
  • Previous aortoiliac surgery or EVAR
  • Recent stroke/MI (\< 3 months)
  • Allergy to device materials
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Technical success of the PERCUTEK Tycheseal™ stent-graft implantation, defined as successful deployment at the intended site with the absence of immediate type I or III endoleaks and no requirement for unplanned conversion to open repair.

    Time frame: 12 months

  2. Freedom from aneurysm sac enlargement, defined as no increase ≥5 mm in the maximum transverse aortic aneurysm diameter at 12 months compared to baseline imaging.

    Time frame: 12 month

  3. Freedom from type I or III endoleaks, confirmed by Doppler ultrasound or angio CT at the 6- and 12-month follow-ups.

    Time frame: 6 and 12 months

  4. Freedom from aneurysm rupture during the 12-month follow-up period.

    Time frame: 12 months

  5. Freedom from stent-graft migration resulting in a serious adverse event or requiring secondary intervention.

    Time frame: 12 months

  6. Freedom from any stent-graft occlusion at 12 months.

    Time frame: 12 months

Secondary outcomes

  1. Aneurysm-related mortality at 12 months

    Time frame: 12 months

  2. All-cause mortality

    Time frame: 30 days; 12 months

  3. Aneurysm sac regression >5 mm at 12 months compared to baseline.

    Time frame: 12 months

  4. Major adverse events (MAEs) at 30 days, 12 months, and 24 months, including: Myocardial infarction, Stroke or transient ischemic attack, New-onset renal failure or dialysis requirement.

    Time frame: 30 days; 12 months; 24 months

  5. All endoleaks (types I, II, III, or undefined origin) detected at 30 days, 12 months, and 24 months.

    Time frame: 30 days; 12 month; 24 months

  6. Reinterventions, categorized as: For treatment of endoleaks, For stent-graft thrombosis or occlusion.

    Time frame: 24 months

  7. Serious adverse device effects (SADEs) throughout the study period.

    Time frame: 24 months

Other outcomes

  1. Device performance metrics as rated by implanting physicians (e.g., ease of use, trackability, radiopacity).

    Time frame: 24 months

  2. Medication adherence, particularly antiplatelet and anticoagulant regimens.

    Time frame: 24 months

07

Study locations

21 of 26 sites recruiting
08

References and documents

Publications

  • Zong NC, Huang K, Yang X, Cai H. Expand the success of screening to reduce aortic aneurysm mortality: progress interpretation and new fronts. Trends Cardiovasc Med. 2025 May;35(4):221-229. doi: 10.1016/j.tcm.2024.12.004. Epub 2024 Dec 13. PubMed 39675687 ↗
  • Ziaja K, Nowakowski P, Simka M. [Repeated excision of abdominal aortic aneurysm--case report]. Wiad Lek. 2000;53(11-12):701-5. Polish. PubMed 11247416 ↗
  • Wierzejski W, Nowakowski P, Drobinski D. Ascending aortic dissection diagnosed with the use of point-of-care sonography. Case report. J Ultrason. 2014 Dec;14(59):428-34. doi: 10.15557/JoU.2014.0045. Epub 2014 Dec 30. PubMed 26673414 ↗
  • Wang S, Fu W, Wang L. First in man: PERCUTEK Tianyi(R) stent-graft greatly facilitated in situ fenestration during thoracic aortic aneurysm endovascular repair. Eur Heart J Case Rep. 2024 Dec 9;9(1):ytae638. doi: 10.1093/ehjcr/ytae638. eCollection 2025 Jan. No abstract available. PubMed 39802051 ↗
  • Troisi N, Pulli R, Donato G, Adami D, Bertagna G, Michelagnoli S, Berchiolli R; ALPHA Abdominal registry Collaborative Group *. Early and Midterm Outcomes of Endovascular Aneurysm Repair With Zenith Alpha Abdominal Stent-Graft: Results From a Multicenter Retrospective Tuscany Registry. J Endovasc Ther. 2025 Jun;32(3):794-801. doi: 10.1177/15266028231197151. Epub 2023 Aug 30. PubMed 37646124 ↗
  • Stokmans RA, Teijink JA, Forbes TL, Bockler D, Peeters PJ, Riambau V, Hayes PD, van Sambeek MR. Early results from the ENGAGE registry: real-world performance of the Endurant Stent Graft for endovascular AAA repair in 1262 patients. Eur J Vasc Endovasc Surg. 2012 Oct;44(4):369-75. doi: 10.1016/j.ejvs.2012.07.005. Epub 2012 Jul 24. PubMed 22835762 ↗
  • Sirignano P, Andreoli F, Gaggiano A, Accarino G, Tusini N, Benedetto F, Veroux P, Silingardi R, Taurino M, Speziale F; AFX2-LIVE Collaborative Study Group. Infrarenal Aortic Treatment With AFX2 Endograft: Results From a Multicentric, International, Non-Randomized, Prospective Registry-the AFX2-LIVE Study. J Endovasc Ther. 2026 Apr;33(2):940-950. doi: 10.1177/15266028241284364. Epub 2024 Oct 6. PubMed 39369322 ↗
  • Reyes Valdivia A, Pitoulias G, Criado FJ, Torsello G, Gandarias C, Austermann M, Pitoulias AG, Donas K. Multicenter European Registry for Patients with AAA Undergoing EVAR Evaluating the Performance of the 36-mm-Diameter Endurant Stent-Graft. Cardiovasc Intervent Radiol. 2017 Oct;40(10):1514-1521. doi: 10.1007/s00270-017-1665-6. Epub 2017 May 1. PubMed 28462441 ↗
  • Rastogi V, Summers SP, Yadavalli SD, Perrier J, Allievi S, Jabbour G, Stangenberg L, de Bruin JL, Jones D, Ferran CJ, Verhagen HJM, Schermerhorn ML. Association between diabetes status and long-term outcomes following open and endovascular repair of infrarenal abdominal aortic aneurysms. J Vasc Surg. 2024 Dec;80(6):1685-1696.e1. doi: 10.1016/j.jvs.2024.08.030. Epub 2024 Aug 23. PubMed 39181338 ↗
  • Nowakowski P, Uchto W, Stolinski J, Gubala M, Legut M. Endovascular treatment of infrarenal aortic aneurysm using the ANKURA stent graft - one-center case series. Postepy Kardiol Interwencyjnej. 2023 Mar;19(1):67-69. doi: 10.5114/aic.2023.124041. Epub 2023 Jan 11. No abstract available. PubMed 37090207 ↗
  • Meuli L, Zimmermann A, Petersen JK, Fosbol EL, Dabravolskaite V, Makaloski V, Eiberg JP, Kober LV, Resch TA. Risk Stratification and Treatment Selection in Patients With Asymptomatic Abdominal Aortic Aneurysms. JAMA Netw Open. 2025 Apr 1;8(4):e253559. doi: 10.1001/jamanetworkopen.2025.3559. PubMed 40193076 ↗
  • Marone EM, Rinaldi LF, Brioschi C, Bracale UM, Modugno P, Maione M, Curci R, Filippi F, Piffaretti G, Gaggiano A, Palasciano G, Angiletta D, Michelagnoli S, Forliti E, Ercolini L, Pulli R; TIGRE REGISTRY GROUP. Endovascular Aortic Repair With the E-Tegra Device: Preliminary Outcomes From a Multicenter National Registry. J Endovasc Ther. 2026 Apr;33(2):710-720. doi: 10.1177/15266028241270861. Epub 2024 Aug 27. PubMed 39188184 ↗
  • Kontopodis N, Gavalaki A, Galanakis N, Kantzas M, Ioannou C, Geroulakos G, Kakisis J, Antoniou GA. Systematic Review With Meta-Analysis of Endovascular Versus Open Repair of Abdominal Aortic Aneurysm Repair in the Young. J Endovasc Ther. 2025 Apr;32(2):276-289. doi: 10.1177/15266028231179419. Epub 2023 Jun 22. PubMed 37350089 ↗
  • Hoshina K. A Multifaceted Approach to Abdominal Aortic Aneurysm. Ann Vasc Dis. 2025;18(1):24-00137. doi: 10.3400/avd.ra.24-00137. Epub 2025 Jan 21. PubMed 39877329 ↗
  • Francisco-Azevedo J, Romana-Dias L, Ribeiro H, Dias-Neto M, Rocha-Neves J. Incidence of Myocardial Injury in Patients Submitted to Abdominal Aortic Aneurysm Repair: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2025 Nov;120:57-76. doi: 10.1016/j.avsg.2025.05.006. Epub 2025 May 10. PubMed 40349833 ↗
  • Capo XF, Garcia Reyes ME, Canovas AS, Besalduch LS, Ruiz DF, Montoya SB; Vascular Advisory Committee - Catalan Health Service. Hospital Volume of Elective Abdominal Aortic Aneurysm Repair as a Predictor of Mortality After Ruptured Abdominal Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg. 2024 Jul;68(1):30-38. doi: 10.1016/j.ejvs.2024.02.034. Epub 2024 Feb 29. PubMed 38428671 ↗
  • Candell L, Tucker LY, Goodney P, Walker J, Okuhn S, Hill B, Chang R. Early and delayed rupture after endovascular abdominal aortic aneurysm repair in a 10-year multicenter registry. J Vasc Surg. 2014 Nov;60(5):1146-1153. doi: 10.1016/j.jvs.2014.05.046. Epub 2014 Jun 21. PubMed 24957409 ↗
  • Besch A, Heckenkamp J, Adili F, Steinbauer M, Cotta L, Behrendt CA. Editor's Choice - Endovascular Treatment of Abdominal Aortic Aneurysm and Impact of Annual Caseload in the Quality Registry of the German Society for Vascular Surgery and Vascular Medicine (DGG). Eur J Vasc Endovasc Surg. 2025 Nov;70(5):567-574. doi: 10.1016/j.ejvs.2025.05.012. Epub 2025 May 10. PubMed 40354966 ↗
  • Bachoo P, Verhoeven EL, Larzon T. Early outcome of endovascular aneurysm repair in challenging aortic neck morphology based on experience from the GREAT C3 registry. J Cardiovasc Surg (Torino). 2013 Oct;54(5):573-80. PubMed 24002386 ↗
  • Alvarez Marcos F, Llaneza Coto JM, Camblor Santervas LA, Zanabili Al-Sibbai AA, Alonso Perez M. Five Year Post-Endovascular Aneurysm Repair Aneurysm Sac Evolution in the GREAT Registry: an Insight in Diabetics Using Propensity Matched Controls. Eur J Vasc Endovasc Surg. 2024 Jun;67(6):912-922. doi: 10.1016/j.ejvs.2023.10.033. Epub 2023 Oct 26. PubMed 37898359 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 67 non-industry observational studies under Aortic Aneurysm, Abdominal, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 12 months is below that.

Counting every sponsor, half of 91 studies reached it within 48 months; a quarter within 24 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2030
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07476196
Lead sponsor
American Heart of Poland
Responsible party
Przemysław Nowakowski (M.D., PhD, Professor, American Heart of Poland) — Principal investigator
First posted
Mar 17, 2026
Start date
Mar 1, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Mar 20, 2026

Study contacts

Przemysław Nowakowski, MD, PhD, Prof
Contact
nowakowski.mcsn@gmail.com
(+48) 32 758 69 01
Przemysław Nowakowski, MD,PhD, Prof
principal investigator · American Heart of Poland

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion